DK1567152T3 - Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose - Google Patents

Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose

Info

Publication number
DK1567152T3
DK1567152T3 DK03783422.3T DK03783422T DK1567152T3 DK 1567152 T3 DK1567152 T3 DK 1567152T3 DK 03783422 T DK03783422 T DK 03783422T DK 1567152 T3 DK1567152 T3 DK 1567152T3
Authority
DK
Denmark
Prior art keywords
rasagilin
riluzol
treatment
lateral sclerosis
amyotroph lateral
Prior art date
Application number
DK03783422.3T
Other languages
English (en)
Inventor
Eran Blaugrund
Ruth Levy
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1567152T3 publication Critical patent/DK1567152T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03783422.3T 2002-11-15 2003-11-13 Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose DK1567152T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42654302P 2002-11-15 2002-11-15
PCT/US2003/036288 WO2004045515A2 (en) 2002-11-15 2003-11-13 Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
DK1567152T3 true DK1567152T3 (da) 2013-10-07

Family

ID=32326373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03783422.3T DK1567152T3 (da) 2002-11-15 2003-11-13 Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose

Country Status (9)

Country Link
US (1) US7396860B2 (da)
EP (2) EP2526944B1 (da)
AU (1) AU2003290838A1 (da)
DK (1) DK1567152T3 (da)
ES (2) ES2432117T3 (da)
IL (1) IL168365A (da)
PT (1) PT1567152E (da)
SI (1) SI1567152T1 (da)
WO (1) WO2004045515A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
ES2432117T3 (es) 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
WO2004105756A2 (en) * 2003-05-29 2004-12-09 Novartis Ag Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
PL1848415T3 (pl) * 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) * 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
HUP0501084A2 (en) * 2005-11-23 2008-05-28 Richter Gedeon Nyrt New pharmaceutical compositions of high effectivity
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
CN101600346B (zh) * 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
EP2325159A1 (en) * 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
WO2011080589A2 (en) * 2009-12-30 2011-07-07 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
JP6045347B2 (ja) * 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
MX2012012069A (es) 2010-04-30 2012-11-22 Teikoku Pharma Usa Inc Composiciones transdermicas de propinilaminoindan.
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
AU2013204200B2 (en) * 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513249A (en) 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5767164A (en) 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5444095A (en) 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
EP0738149B1 (en) 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
AU2472499A (en) 1998-01-27 1999-08-09 Thomas N. Thomas Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
US20040052843A1 (en) 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP2005523289A (ja) 2002-02-27 2005-08-04 テバ ファーマシューティカル インダストリーズ リミティド 脳選択性ｍａｏ阻害剤としてのプロパルギルアミノインダン誘導体及びプロパルギルアミノテトラリン誘導体
AU2003272066A1 (en) 2002-10-16 2004-05-04 Alon Bear Smart card network interface device
ES2432117T3 (es) 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
CN1878912B (zh) 2003-10-15 2010-12-08 日本制纸株式会社 铸涂纸及其制造方法
US7735024B2 (en) 2003-10-29 2010-06-08 Intel Corporation Methods and apparatus to provide a handheld pointer-based user interface
WO2006014973A2 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ATE521343T1 (de) 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity

Also Published As

Publication number Publication date
EP2526944A1 (en) 2012-11-28
SI1567152T1 (sl) 2013-10-30
ES2588780T3 (es) 2016-11-04
ES2432117T3 (es) 2013-11-29
EP1567152A4 (en) 2008-05-14
US7396860B2 (en) 2008-07-08
US20040127577A1 (en) 2004-07-01
WO2004045515A3 (en) 2004-07-29
IL168365A (en) 2010-12-30
AU2003290838A1 (en) 2004-06-15
AU2003290838A8 (en) 2004-06-15
WO2004045515A2 (en) 2004-06-03
PT1567152E (pt) 2013-10-03
EP1567152B1 (en) 2013-08-14
EP2526944B1 (en) 2016-06-01
EP1567152A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
DK1567152T3 (da) Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1755661T3 (da) Gelsolin til anvendelse til behandling af infektioner
DK1647529T3 (da) Fremgangsmåde til oprensing af spildevand
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
NO20034941D0 (no) Renseanlegg for varmekraftverk
DK1546045T3 (da) Styring af spildevandsbehandlingsprocesser
DK1643998T3 (da) NK1/NK3-antagonister til behandling af skizofreni
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1539200T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DK1516596T3 (da) Forbedret system til behandling af stress-urinkontinens
DK1578774T3 (da) Oprensning af immunoglobuliner
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK1492501T3 (da) Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål